Researchers from the University of Lund, Sweden, have developed a new type of treatment for aggressive breast cancer, which involves the use of a drug that attacks the formation, spread and resistance of this type of cancer.
According to the study, published in the journal Nature Medicine, between 10 and 15% of breast cancers are less sensitive to more conventional hormonal therapies, which are usually used to treat 70% of less aggressive cancer cases.
Kristian Pietras, director of the team responsible for the research, explains that this new drug will help develop more effective treatments, because it increases the sensitivity of cancer cells.
The drug blocks communication between breast cancer cells and those of the surrounding connective tissue. This is a very important type of communication that they have managed to observe in more than 1,500 cases of basal breast cancer; therefore the importance of its interruption.
Furthermore, the specialist highlights that one of the most recurrent problems in cases of basal breast cancer is that an erroneous prognosis is made, due to the presence of a growth factor (PDGF-CC) whose interference was not fully understood.
In this regard, Ulf Ericksson, a researcher at the Karoslinska Institute in Stockholm and participant of the study, reveals that the finding is extremely important because the cells of the connective tissue can directly modify the tumors, with respect to their sensitivity to hormonal treatments.
For the Swedish researchers, which are joined by experts from Australia and Germany, this opens a great possibility for the development of better hormonal treatments against aggressive breast cancer and drugs that provide more remarkable results for patients.
According to the CDC, 236,968 women and 2,141 men in the United States were diagnosed with breast cancer in 2014, the most recent statistical year. 41,211 women and 465 men in the United States died from breast cancer in that same year.